Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NZ71
UPID:
RTEL1_HUMAN
Alternative names:
Novel helicase-like
Alternative UPACC:
Q9NZ71; A2A397; A2A398; B4DRM5; B4DYM3; B4E3N6; E1P5J4; E1P5J5; Q5JTV3; Q5JTV4; Q9BW37; Q9H402; Q9H4X6; Q9NX25; Q9NZ73; Q9UPR4; Q9Y4R6
Background:
Regulator of telomere elongation helicase 1 (RTEL1), also known as Novel helicase-like, plays a crucial role in telomere-length regulation, DNA repair, and maintaining genomic stability. It acts as an anti-recombinase, limiting crossover during meiosis and ensuring telomere dynamics and stability by counteracting telomeric G4-DNA structures.
Therapeutic significance:
RTEL1's involvement in diseases like Dyskeratosis congenita and Pulmonary fibrosis, linked to defective telomere maintenance, highlights its potential as a target for therapeutic strategies. Understanding RTEL1's function could lead to breakthroughs in treating these genetic disorders.